Clinical Trial

Phase 1a Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RN5681 in Healthy Volunteers

Name: Phase 1a Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RN5681 in Healthy Volunteers — clinical trial record (NCT07347678)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Recruiting Phase 1

View on ClinicalTrials.gov →

Summary

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and immunogenicity of single doses of RN5681 in Adult healthy subjects

Protocol Amendment History 1 change

critical Recruitment opened 2026-04-04

Trial Details

NCT Number	NCT07347678
Lead Sponsor	Ikaria Bioscience Pty Ltd Collaborators: Shanghai Rona Therapeutics Co., Ltd.
Conditions	High Cholesterol
Enrollment	60 participants
Start Date	2026-03-12
Primary Completion	2027-02 (estimated)
Study Completion	2027-07 (estimated)
Updated on ClinicalTrials.gov	2026-04-03